Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The CEO of Swiss pharmaceutical company Roche injected himself into the controversy surrounding Novo Holdings' planned $16.5 billion acquisition of Catalent on Wednesday, stating that he thinks antitrust authorities should block the deal. https://t.co/yu4GjAiqNE https://t.co/j9F7rX8fCJ
$nvo $ctlt Roche ceo so worried about merger hes sold his own company a clown 🤡 https://t.co/MWbW5toVxc
Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers https://t.co/TgkdjcAiu9
The CEO of Roche, a leading Swiss pharmaceutical company, has publicly opposed Novo Holdings' proposed $16.5 billion acquisition of contract drug manufacturer Catalent. The CEO expressed concerns that the takeover could negatively impact smaller drugmakers, urging antitrust authorities to intervene and block the deal. This statement highlights Roche's apprehension regarding the consolidation within the pharmaceutical industry and its potential effects on competition among industry peers.
